Optic nerve glioma primary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
(Mahshid)
 
(6 intermediate revisions by one other user not shown)
Line 5: Line 5:
Effective measures for the primary prevention of optic nerve glioma include regular [[eye]] exams in patients with [[neurofibromatosis]] type 1.
Effective measures for the primary prevention of optic nerve glioma include regular [[eye]] exams in patients with [[neurofibromatosis]] type 1.
==Primary Prevention==
==Primary Prevention==
Optic pathway glioma occurs in 15 percent of patients with [[neurofibromatosis]] 1. Regular eye exams may allow early diagnosis of these [[tumors]] before they cause symptoms. Ophthalmologic screening should include confrontation [[visual]] [[field]] testing, color vision testing, visual acuity testing, and assessment of pupils, eyelids, irises, fundi, and extraocular motility. The evaluation should begin when neurofibromatosis type 1 first is suspected and should be repeated at annual intervals or when symptoms develop. Clinical evaluation in patients with NF-1 appears to be more useful to detect complications than are [[screening]] investigations in asymptomatic patients.<ref name="pmid9207339">{{cite journal| author=Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE et al.| title=The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. | journal=JAMA | year= 1997 | volume= 278 | issue= 1 | pages= 51-7 | pmid=9207339 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9207339  }} </ref><ref name="pmid8915311">{{cite journal| author=Wolkenstein P, Frèche B, Zeller J, Revuz J| title=Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients. | journal=Arch Dermatol | year= 1996 | volume= 132 | issue= 11 | pages= 1333-6 | pmid=8915311 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8915311  }} </ref> The optimal care for individuals with [[NF1]] aims at the symptomatic treatment and early detection of complications as they occur. Genetic counseling may be advised for people with neurofibromatosis type 1. All children with NF1 should undergo regular growth assessments using standard growth charts.<ref name="pmid10588837">{{cite journal| author=Clementi M, Milani S, Mammi I, Boni S, Monciotti C, Tenconi R| title=Neurofibromatosis type 1 growth charts. | journal=Am J Med Genet | year= 1999 | volume= 87 | issue= 4 | pages= 317-23 | pmid=10588837 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10588837  }} </ref>  
*Optic pathway glioma occurs in 15 percent of patients with [[neurofibromatosis]] 1. Regular eye exams may allow early diagnosis of these [[tumors]] before they cause symptoms.
*Ophthalmologic screening should include confrontation [[visual field]] testing, color vision testing, [[visual acuity]] testing, and assessment of [[pupils]], eyelids, irises, fundi, and extraocular motility.
*The evaluation should begin when neurofibromatosis type 1 first is suspected and should be repeated at annual intervals or when symptoms develop. Clinical evaluation in patients with NF-1 appears to be more useful to detect complications than are [[screening]] investigations in asymptomatic patients.<ref name="pmid9207339">{{cite journal| author=Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE et al.| title=The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. | journal=JAMA | year= 1997 | volume= 278 | issue= 1 | pages= 51-7 | pmid=9207339 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9207339  }} </ref><ref name="pmid8915311">{{cite journal| author=Wolkenstein P, Frèche B, Zeller J, Revuz J| title=Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients. | journal=Arch Dermatol | year= 1996 | volume= 132 | issue= 11 | pages= 1333-6 | pmid=8915311 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8915311  }} </ref>
*The optimal care for individuals with [[NF1]] aims at the symptomatic treatment and early detection of complications as they occur. [[Genetic counseling]] may be advised for people with neurofibromatosis type 1. All children with NF1 should undergo regular growth assessments using standard growth charts.<ref name="pmid10588837">{{cite journal| author=Clementi M, Milani S, Mammi I, Boni S, Monciotti C, Tenconi R| title=Neurofibromatosis type 1 growth charts. | journal=Am J Med Genet | year= 1999 | volume= 87 | issue= 4 | pages= 317-23 | pmid=10588837 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10588837  }} </ref>


==References==
==References==
Line 14: Line 17:
[[Category:Neurology]]
[[Category:Neurology]]
[[Category:Ophthalmology]]
[[Category:Ophthalmology]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Ophthalmology]]
[[Category:Neurosurgery]]

Latest revision as of 14:48, 27 November 2017

Optic nerve glioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Optic nerve glioma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Optic nerve glioma primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Optic nerve glioma primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Optic nerve glioma primary prevention

CDC on Optic nerve glioma primary prevention

Optic nerve glioma primary prevention in the news

Blogs on Optic nerve glioma primary prevention

Directions to Hospitals Treating Optic nerve glioma

Risk calculators and risk factors for Optic nerve glioma primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]

Overview

Effective measures for the primary prevention of optic nerve glioma include regular eye exams in patients with neurofibromatosis type 1.

Primary Prevention

  • Optic pathway glioma occurs in 15 percent of patients with neurofibromatosis 1. Regular eye exams may allow early diagnosis of these tumors before they cause symptoms.
  • Ophthalmologic screening should include confrontation visual field testing, color vision testing, visual acuity testing, and assessment of pupils, eyelids, irises, fundi, and extraocular motility.
  • The evaluation should begin when neurofibromatosis type 1 first is suspected and should be repeated at annual intervals or when symptoms develop. Clinical evaluation in patients with NF-1 appears to be more useful to detect complications than are screening investigations in asymptomatic patients.[1][2]
  • The optimal care for individuals with NF1 aims at the symptomatic treatment and early detection of complications as they occur. Genetic counseling may be advised for people with neurofibromatosis type 1. All children with NF1 should undergo regular growth assessments using standard growth charts.[3]

References

  1. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE; et al. (1997). "The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2". JAMA. 278 (1): 51–7. PMID 9207339.
  2. Wolkenstein P, Frèche B, Zeller J, Revuz J (1996). "Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients". Arch Dermatol. 132 (11): 1333–6. PMID 8915311.
  3. Clementi M, Milani S, Mammi I, Boni S, Monciotti C, Tenconi R (1999). "Neurofibromatosis type 1 growth charts". Am J Med Genet. 87 (4): 317–23. PMID 10588837.

Template:WH Template:WS